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Immune activation is the hallmark of HIV infection, even in patients with highly active
anti-retroviral therapy (HAART)-induced viral suppression. A major cause of immune
activation during HIV infection is the intestinal microbial translocation as a consequence,
among other factors, of the decrease and/or dysfunction of interleukin (IL)-17-producing
T-cells, due to their role promoting the integrity of the intestinal barrier. A population of
IL-17-producing CD8+ T-cells (Tc17 cells), characterized by the expression of CD161,
has been described, but its relation with the persistent immune activation in non-viremic
people living with HIV (PLWH) on HAART is unclear. By flow cytometry, we characterized
the activation phenotype (evaluated by the expression of HLA-DR and CD38) of
circulating CD161-expressing CD8+ T-cells; in addition, we explored the functionality
of polyclonally-stimulated Tc17 cells in PLWH under HAART-induced viral suppression,
and in healthy individuals. Finally, we determined the association of Tc17 cells with
the expression of cellular and soluble activation markers. Circulating CD161-expressing
CD8+ T-cells were decreased in PLWH compared with healthy individuals, despite
their similar basal activation state. After polyclonal stimulation, IL-17 production was
higher in CD8+ T-cells co-expressing HLA-DR and CD38 in healthy individuals. In
contrast, although PLWH had a higher frequency of HLA-DR+ CD38+ CD8+ T-cells after
stimulation, they had a lower production of IL-17. Interferon (IFN)-γ-producing CD8+
T-cells (Tc1 cells) were increased in PLWH. The low Tc17 cells response was associated
with a high expression of CD38 and programmed death 1 protein, high levels of
soluble CD14 and the treatment duration. Finally, to explore potential immunomodulatory
strategies, the in vitro effect of the anti-inflammatory agent sulfasalazine was assessed
on Tc17 cells. Interestingly, a decreased inflammatory environment, death of activated
CD8+ T-cells, and an increased frequency of Tc17 cells were observed with sulfasalazine
treatment. Thus, our findings suggest that activated CD8+ T-cells have amarked capacity
to produce IL-17 in healthy individuals, but not in PLWH, despite HAART. This dysfunction
of Tc17 cells is associated with the persistent immune activation observed in these
patients, and can be partially restored by anti-inflammatory agents.
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INTRODUCTION
During human immunodeficiency virus type 1 (HIV) infection,
microbial translocation, residual HIV replication or co-infections
trigger and maintain the persistent inflammatory environment
and the immune activation state, even in patients with viral
suppression induced by the highly active anti-retroviral therapy
(HAART). These alterations result in an incomplete immune
reconstitution, despite continuous therapy (1, 2). As other
immune cells, CD8+ T-cells are highly affected by the activation
state, evidenced by higher levels of apoptosis, exhaustion and/or
dysfunctionality (3, 4). In this sense, the expression of HLA-
DR and CD38 have been widely used to assess the activation
levels of CD8+ T-cells (5–7). Interestingly, some subpopulations
have been reported based on the expression of these markers,
where the CD38 expression alone and the co-expression of
both molecules are associated to a higher dysfunctional state,
in comparison with the unique expression of HLA-DR or the
absence of both markers. Thus, HLA-DR+ CD38+ CD8+ T-cells
from people living with HIV (PLWH) have lower cytotoxicity
and non-lytic effector functions (such as the simultaneous
production of cytokines) compared with HLA-DR+ CD38− cells
(8).
Based on the cytokines produced, several subpopulations
of CD8+ T-cells, such as interferon (IFN)-γ-producing (Tc1)
cells have been described. Particularly, Interleukin-17A (IL-17)-
producing CD8+ T (Tc17) cells, characterized by the expression
of CD161 (9), exhibit altered systemic frequency and function
during HIV infection (10), similar to their CD4+ T-cells
counterparts (Th17 cells) (11). The IL-17 has several beneficial
effects in the intestinal tract, such as the promotion of tight
junctions in epithelial cells (12), the secretion of anti-microbial
peptides (13), as well as recruitment of immune cells to sites of
mucosal injury (14). Therefore, during HIV infection, the lower
availability of IL-17 worsens the disruption of the gut barrier and
the consequent microbial translocation and immune activation.
Although HAART has contributed dramatically to decrease
the acquired immunodeficiency syndrome (AIDS)-related
deaths, non-AIDS conditions, with a large inflammatory
component, persist in treated PLWH and are a major cause of
morbidity and death in these individuals (15, 16). Thus, the
search for immunomodulatory agents is one of the main research
fields in the context of HAART-induced suppression of HIV
replication (17). For instance, anti-inflammatory molecules such
as acetylsalicylic acid, statins and hydroxychloroquine have been
evaluated in PLWH on HAART to modulate the activation of
monocytes (18), the expression of T-cell activation markers (19),
and the reduction of inflammatory cytokines such as IL-6 and
tumor necrosis factor (TNF)-α (20). In this sense, sulfasalazine
(SSZ) is an anti-inflammatory agent which combines the
antibiotic sulphapyridine with 5-aminosalicylic acid, and has
been widely used in the treatment of rheumatoid arthritis and
inflammatory bowel disease (21). Although its mechanism of
action has not been completely elucidated, it has been shown to
inhibit macrophage activation (22) and secretion of TNF-α (23);
in addition, it induces apoptosis of activated T-cells (24). Thus,
SSZ has the potential to modulate the inflammatory state in
PLWH, reducing the proportion of activated and dysfunctional
cells.
In this study we evaluated the frequency, phenotype and
function of CD161-expressing CD8+ T-cells and Tc17 cells in
PLWH under suppressive HAART. Overall, we hypothesized
that despite HAART-induced viral suppression, PLWH have
alterations in these parameters, compared with healthy controls.
Certainly, despite treatment, PLWH had a decreased function of
activated Tc17 cells and a low Tc17/Tc1 cells ratio compared with
HIV-seronegative healthy volunteers, that correlated with high
cellular and plasma immune activation levels. This dysfunction
was particularly associated with the expression of CD38 and the
programmed death 1 protein (PD-1). A potential beneficial effect
of SSZ in the restoration of these subsets was observed. The Tc17
response is proposed as a novel cellular correlate of systemic
immune activation in PLWHunder HAART, as well as a potential
target for the improvement of immune reconstitution in these
individuals.
METHODS
Patients and Samples
The Ethical Committee of Sede de Investigación Universitaria,
Universidad de Antioquia (certificates 15-08-634 and 11-
08-352) approved this study. Written informed consent
was obtained from all donors. All procedures followed the
principles expressed in the Declaration of Helsinki. PLWH
on suppressive HAART (n = 30) were included; all of them
had a viral load <50 HIV RNA copies/mL for more than one
year, reached this level in less than 26 weeks of treatment,
and received only one therapeutic scheme throughout this
time (56.6% receiving abacavir/lamivudine/efavirenz; 26.6%
on efavirenz/emtricitabine/tenofovir, and 16.6% receiving
raltegravir/tenofovir/emtricitabine). At the time of study
enrollment, none of them was receiving other medications
concomitantly, and none had developed therapeutic failure,
AIDS-defining diseases or non-AIDS conditions, such as
cardiovascular disease, neurocognitive disorders, malignancies
or clinically evident co-infections. Hepatitis B or C virus co-
infections were not discarded, but none of them have signs
of clinical hepatitis. In all of the subjects, the mode of HIV
transmission was sexual. Table 1 shows the characteristics
of the study cohort. A group of HIV-seronegative healthy
volunteers were included as controls (n = 15). To each
individual, a complete medical examination and complete
blood cell count was performed to exclude clinical failure
(in PLWH) or disease (healthy individuals). From each
individual, 10mL of venous blood was collected in EDTA-
containing tubes and the phenotyping of circulating T-cells
was performed immediately. A fraction of the blood was
centrifuged at 300 x g, and the plasma was used for determining
viral load with the approved clinical diagnostic test RT-PCR
Ampliprep-Cobas (Roche, Indianapolis, IN, USA), following
the manufacturer’s protocol, with a detection limit of 20
copies/mL, and for the quantification of soluble CD14 (sCD14).
The cellular fraction was used for the isolation of peripheral
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TABLE 1 | Characteristics of the study cohort.
Parameter Healthy
(n = 15)
PLWH
(n = 30)
P-value
Age, years; median
(range)
27 (23–33) 30 (22–61) 0.1a
Men: Women 14: 1 30: 0 0.3b
CD4+ T-cells/µL, median
(range)
634 (475–1330) 504 (428–1213) 0.009a
CD8+ T-cells/µL, median
(range)
460 (174–911) 737 (268–1250) 0.001a
CD4:CD8 ratio, median
(range)
2 (1.1–2.8) 0.7 (0.3–1.5) <0.0001a
Diagnosis time, months;
median (range)
N/A 26 (15–288) N/A
Treatment time, months;
median (range)
N/A 24 (14–159) N/A
aMann-Whitney test. bFisher’s test. N/A, Does not apply.
blood mononuclear cells (PBMC). In some experiments, it
was not possible to include all the individuals due to sample
limitations.
Flow Cytometry
One hundred µL of whole blood was incubated for 30min
at room temperature with optimized doses and combinations
of the following mouse anti-human antibodies: phycoerythrin
(PE)-labeled anti-CD8 (clone RPA-T8), allophycocyanin (APC)-
labeled anti-CD161 (clone DX12; both from BD, San Jose,
CA, USA), Alexa Fluor 700-labeled anti-CD3 (clone UCHT1),
APC-eFluor 780-labeled anti-CD4 (clone RPA-T4), fluorescein
isothiocyanate (FITC)-labeled anti-HLA-DR (clone LN3), PE
Cy7-labeled anti-CD38 (clone HIT2) and peridinin-chlorophyll-
protein complex (PerCP)-eFluor 710-labeled anti-PD-1 (clone
F38-2E2; all from Thermo Fisher, Waltham, MA, USA).
Next, red blood cells were eliminated with 1X FACS Lysing
Solution (BD) for 20min at room temperature, followed by a
washing step with with 1mL of 1X PBS and fixation in 1%
paraformaldehyde. The cells were acquired on a LSR Fortessa
cytometer (BD), using the FACS Diva software v. 6.0, within
1 h of completing the staining; at least 50,000 CD3+ events
were acquired. The data were analyzed with the FlowJo Software
version 10.4 (Tree Star, Inc, Ashland, OR, USA). Fluorescence
minus one (FMO) controls were included to define positive
thresholds.
Ex Vivo Stimulation and Detection of
Cytokine-Producing T-Cells
Peripheral blood mononuclear cells were isolated using a Ficoll
density gradient (Ficoll Histopaque-1077, Sigma-Aldrich, St.
Louis, MO) and washed with RPMI-1640 supplemented with
10% fetal bovine serum, 100 U/mL of penicillin, 100µg/mL
of streptomycin and 2mM L-glutamine (complete medium; all
from Gibco, Carlsbad, CA). Immediately, 2 × 106 cells/mL were
stimulated in 96 well V-bottom plates (Costar, Corning, NY) with
mouse anti-human CD28 and CD49d functional grade purified
antibodies alone (both at 1µg/mL; clones CD28.2 and 9F10,
respectively, both from eBioscience; used as negative control),
anti-CD28 and anti-CD49d plus a pool of HIV-1 consensus
B Gag peptides (at 5µg/mL; obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH; Cat: 8117,
Lot: 140303) or with phorbol 12-myristate 13-acetate (PMA)
and ionomycin (at 50 and 500 ng/mL, respectively; both from
Sigma-Aldrich) and incubated for 12 h at 37 ◦C in 5% CO2, all
in the presence of 5µg/mL of Brefeldin A and monensin (both
from eBioscience). After incubation, the viability was higher
than 90% (assessed by Trypan blue exclusion staining). Next,
the PBMC were harvested and washed with 2mL of 1X PBS.
Afterwards, the following mouse anti-human antibodies were
added for cell surface staining and incubated for 30min at 4◦C,
light-protected: PerCP-labeled anti-CD3 (clone SK7, BD), Alexa
Fluor 700-labeled anti-CD8 (clone OKT8), APC-eFluor 780-
labeled anti-HLA-DR (clone LN3) and PE-eFluor 610-labeled
anti-CD38 (clone HIT2; all from Thermo Fisher). In a fraction
of the individuals, APC-labeled anti-CD161 (clone DX12, BD)
was also included. After cell fixation and permeabilization with
Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher)
and blockade with 10 µL of Fc Receptor Binding Inhibitor
Polyclonal Antibody (Thermo Fisher), standardized doses of
brilliant violet (BV) 510-labeled mouse anti-human IL-17A
(clone N49-653, BD) and PE-Cy7-labeled mouse anti-human
IFN-γ (clone 4S.B3, Thermo Fisher) were added and incubated
for 30min at 4◦C, light-protected. Finally, the cells were washed
twice with 1X permeabilization solution (Thermo Fisher) and
acquired on a LSR Fortessa cytometer (BD). At least 25,000 CD3+
CD8+ events were acquired. Fluorescence minus one controls
were also included. The background of the non-stimulated
cells was subtracted from the stimulated condition. Finally,
median fluorescence intensities (MeFI) of the respective markers
were evaluated, ensuring comparable fluorochrome channels
voltages.
ACCENSE Analysis
Automatic Classification of Cellular Expression by Nonlinear
Stochastic Embedding (ACCENSE) analyses were performed
to determine the phenotypic relationships from the cell
populations evaluated (25), using the ACCENSE 0.0.5-beta
software. Data were exported from FlowJo as FCS files and
the Barnes-Hut-Stochastic Neighbor Embedding (t-SNE) was
used for dimensionality reduction, with perplexity set to
30, and down sampling to 30,000 cells. t-SNE plots were
colored according to the expression of chosen channel. For
correlation analyses, the channels relative expression units of
input were collected from a fraction of cells of all the healthy
individuals and PLWH (M = 60,000 cells in each group) and
computed.
Measurement of sCD14 Levels in Plasma
and IL-1β in Culture Supernatant
The Human sCD14 ELISA Kit (MyBioSource, San Diego,
CA), and BD OptEIA Human IL-1β ELISA Set II (BD) were
used to measure sCD14 in plasma and IL-1β in culture
supernatants, following the manufacturer’s protocols. The limits
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of detection for sCD14 and IL-1β were 0.18 ng/mL and 4.5
pg/mL, respectively.
Sulfasalazine Treatment
Peripheral blood mononuclear cells at a density of 2 × 106
cells/mL were treated with 100 ng/mL of the Toll-like receptor
4 (TLR4) ligand E. coli lipopolysaccharide (LPS; Invivogen,
San Diego, CA) in the presence or absence of 1mM SSZ
(Sigma-Aldrich, St. Louis, MO), and incubated for 24 h at 37◦C
in 5% CO2. The concentration of SSZ and the incubation
time were selected after evaluation of cellular toxicity, where
<1% of PBMC mortality [evaluated by Trypan blue exclusion
staining and Fixable Viability Dye eFluor 506 (eBioscience)]
was obtained at the chosen condition (n = 5, data not shown).
Subsequently, the cells were stimulated with PMA and ionomycin
(at 50 and 500 ng/mL, respectively), and incubated for 12 h at
37◦C in 5% CO2, all in the presence of 5µg/mL of Brefeldin
A and monensin, previous evaluation of cell viability with
the Fixable Viability Dye eFluor 506. Finally, the cells were
harvested, followed by surface and intracellular staining, as
described above. In a fraction of individuals, PBMC were
cultured with LPS plus SSZ in the presence or absence of the
caspase-1 inhibitor Ac-YVAD-cmk or the pan-caspase inhibitor
Z-VAD-FMK (at 0.25 and 5µg/mL, respectively; both from
InvivoGen), and the type of cell death was evaluated with the
TACS Annexin V Kits (Trevigen), following the manufacturer’s
instructions.
Statistical Analysis
Data are presented as medians and ranges. The Mann-Whitney
andWilcoxon tests were used for comparison of two independent
or paired data, respectively, and the Kruskal-Wallis test for more
than two independent groups. If the Kruskal-Wallis P-value was
<0.05, the Dunn’s multiple comparison test was performed. The
degree of correlation between variables was determined with the
Spearman and Pearson tests. Fisher’s and Chi Square tests were
used for frequency analysis. For statistical purposes, in samples
with undetectable sCD14 and IL-1β levels, a value equal to the
half of the assay limit of detection was assigned. In all cases, a
P-value <0.05 was considered significant. The GraphPad Prism
software v. 7.0 (GraphPad Software, La Jolla, CA) was used for
the statistical analysis.
RESULTS
Low Frequency of Circulating
CD161-Expressing CD8+ T-Cells in PLWH
CD161 was used as a surrogate marker for Th17 and Tc17
cells, as previously reported (10) and following the gating
strategy showed in Figure 1A. Similar to a previous report (26),
CD161+ and CD161hi CD8+ T-cells, but not CD4+ T-cells,
were identified, based on a 2-fold difference in the MeFI of
CD161 between these subsets. The relative frequency of these cell
populations (Figure 1A), as well as MeFI of CD161 (P≤0.001,
data not shown) were decreased in PLWH in comparison with
healthy controls. To explore the activation profile of these
subsets, the expression of HLA-DR and CD38, classically used
to assess T-cell activation, was evaluated by ACCENSE t-SNE
analysis. As shown in Figure 1B, t-SNE plots of all collected
parameters in cells from a healthy individual and a subject
living with HIV showed association of CD161 with CD3 and
CD4 expression, and in a lesser extent with CD8 expression.
Interestingly, CD161-positive cells were not related to those
expressing HLA-DR and CD38, in either CD4+ or CD8+ T-cells.
In fact, CD161+ (Figure 1C) and CD161hi (Figure 1D) CD8+
T-cells predominantly lacked the expression of both activation
markers. Non-significant differences were observed in HLA-
DR and/or CD38-expressing CD161-expressing CD8+ T-cell
populations between healthy controls and PLWH, except for a
lower frequency of HLA-DR+ CD38− CD161+ CD8+ T-cells in
PLWH (Figure 1C). Together, these results indicate that, despite
HAART, a lower frequency of non-activated CD161-expressing
CD8+ T-cells is found in PLWH.
Compared With Healthy Controls, PLWH
Under HAART-Induced Viral Suppression
Have Conserved Total Tc17 Cells
To confirm the findings obtained with the analysis of CD161,
we directly assessed the frequency of HIV-specific and total
Tc17 cells after Gag peptides and PMA-ionomycin stimulation,
respectively, following the gating strategy of Figure 2A. The
frequency of Tc1 cells was also evaluated (Figure 2A). As
shown in Figure 2B, a low, but detectable, frequency of HIV-
specific Tc17 and Tc1 cells was found in PLWH, with no
differences between both subsets (P = 0.4, data not shown).
As expected, we did not detect HIV-specific Tc17 or Tc1
cells in healthy individuals (Figures 2A, B). The frequency of
total Tc17 and Tc1 cells was similar between PLWH and
healthy controls (Figure 2C). In addition, we did not observe
differences in the MeFI of IL-17 and IFN-γ in total and
HIV-specific Tc17 and Tc1 cells, respectively (P≥0.1, data not
shown). Similarly, a comparable total Tc17/Tc1 cells ratio (as
a measure of the predominant CD8+ T-cell subset) was found
between healthy individuals and PLWH (P = 0.1, data not
shown).
To determine the significance of the lower frequency of
CD161-expressing CD8+ T-cells but conserved frequency of
total Tc17 cells, the expression of CD161 was evaluated in IL-
17+ and IFN-γ+ CD8+ T-cells. As shown in Figure 2D, and
similar to a previous report (9), IL-17+ CD8+ T-cells from
healthy individuals had a higher expression of CD161 than
IFN-γ+ CD8+ T-cells. Nonetheless, we extensively observed a
decrease in the frequency of CD161-expressing CD8+ T-cells
after polyclonal stimulation (Figure 2E). In order to evaluate
if CD161 was internalized after stimulation, we evaluated its
expression when the anti-CD161 antibody was added pre and
post cell permeabilization. Post-permeabilized stained cells had a
higher frequency of CD161-expressing CD8+ T-cells compared
with pre-permeabilized stained cells, and they produced both
IL-17 and IFN-γ (Figure 2E). In extent, when we correlated
the frequency of total Tc17 with that of CD161+ CD8+ T-
cells, a low and lack of correlation was found in PLWH and
healthy individuals, respectively (Figure 2F, upper panel), similar
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FIGURE 1 | Low frequency of circulating non-activated CD161-expressing CD8+ T-cells in PLWH. (A) Gating strategy for the detection of circulating
CD161-expressing CD4+ and CD8+ T-cells. Representative pseudocolor plots from a healthy individual and a subject living with HIV are shown. Peripheral blood
lymphocytes were first gated and duplicates were excluded (FSC-A/FSC-H). T-cells were identified as CD3+. The numbers next to the gates indicate the percentage
of the respective population. At the right of each plot is shown the summary of the frequency of CD161-expressing CD4+ and CD8+ T-cells in healthy individuals and
PLWH. (B) Cell ACCENSE t-SNE plots of CD3, CD4, CD8, CD161, HLA-DR, and CD38 expression in cells from a representative healthy individual and a subject living
with HIV (M = 30,000). The black and red circles indicate, respectively, CD161-positive CD4+ and CD8+ T-cells. (C,D) Frequency of HLA-DR- and/or
CD38-expressing CD161+ (C) and CD161hi (D) CD8+ T-cells in healthy individuals and PLWH. In (A,C,D) the P-value of the Mann-Whitney test is shown. NS, Not
statistically significant.
to the equivalent comparison with total Tc1 cells (Figure 2F,
lower panel). On the contrary, a positive correlation between
the frequency of HIV-specific Tc17 cells and that of CD161+
CD8+ T-cells was found (Figure 2G). In summary, although the
frequency of CD161-expressing CD8+ T-cells is decreased in
PLWH on HAART, the total Tc17 response is maintained. In
addition, the expression of CD161 is not a good surrogate marker
of total Tc17 cells after PMA-ionomycin stimulation because
it is internalized with these potent stimuli. In the case of a
less potent stimulation, such as HIV peptides, a low correlation
between HIV-specific Tc17 cells response and CD161 expression
was observed.
Among Total CD8+ T-Cells, Those With an
Activated Phenotype Are the Main Source
of IL-17, and Are Dysfunctional in PLWH
Although CD8+ T-cells from PLWH on HAART exhibited
a low activation profile, it is possible that their activation
threshold is lower than that of CD8+ T-cells from healthy
individuals. Thus, we evaluated the expression of HLA-DR and
CD38 in CD8+ T-cells in the presence or absence of PMA-
ionomycin. Similar to previous reports (27, 28), the frequency
of HLA-DR+ and/or CD38+ CD8+ T-cells increased after
polyclonal stimulation, with the decrease of double negative cells,
both in PLWH and healthy individuals (Figure 3A and data
not shown). Of note, HLA-DR+ and CD38+ cells increased
the most after stimulation, evidenced by the delta of the
PMA-ionomycin/non-stimulated cells frequency (Figure 3A);
however, their proportion, as well as that of HLA-DR+ CD38−
cells, were higher in PLWH (Figure 3B). Thus, CD8+ T-cells
from PLWH are prone to activation after ex vivo polyclonal
stimulation.
To explore if the higher activation levels post-stimulation
in CD8+ T-cells from PLWH affected their ability to produce
IL-17, we evaluated the magnitude of total HLA-DR+ and/or
CD38+ Tc17 cells. In healthy individuals and PLWH, a high
percentage of IL-17+ cells expressed the HLA-DR+ CD38+
phenotype (Figure 3C). In contrast, most of IFN-γ cells exhibited
the HLA-DR+ CD38− phenotype (Figure 3C). Similarly, HLA-
DR+ CD38+ CD8+ T-cells had the highest production of
IL-17 among total CD8+ T-cells when compared with HLA-
DR− CD38+, HLA-DR+ CD38− and HLA-DR− CD38− cells
(Figures 3D,E). Nonetheless, despite the higher frequency of
HLA-DR+ CD38+ CD8+ T-cells in PLWH, their production
of IL-17 cells was lower, as well as that of HLA-DR− CD38+
cells (Figures 3D,E). On the other hand, HLA-DR+ CD38− cells
were the major producers of IFN-γ among HLA-DR/CD38-
expressing CD8+ T-cells, and the frequency of this subset was
similar between PLWH and healthy controls (Figures 3D,F).
Interestingly, the total Tc17/Tc1 cells ratio, according to the
expression of HLA-DR and CD38, was decreased in PLWH in
comparison with healthy controls in HLA-DR− CD38+ cells
(Figure 3G). Similar to total Tc17 cells, HIV-specific HLA-
DR+ CD38+ CD8+ T-cells exhibited the highest production
of IL-17 (Figures 3H,I), similar to Tc1 cells (Figures 3H,J),
with comparable frequencies between both subsets, as evidenced
by a HIV-specific Tc17/Tc1 cells ratio near to 1 in all
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FIGURE 2 | Conserved frequency of total Tc17 cells in PLWH on suppressive HAART. (A) Gating strategy for the detection of total and HIV-specific Tc17 and Tc1
cells. Representative zebra plots from non-stimulated, HIV Gag peptides- and PMA-ionomycin-treated cells from a healthy individual and a subject living with HIV are
shown. After duplicates exclusion (FSC-A/FSC-H), CD8+ T-cells were identified as CD3+ CD8+ cells. The numbers next to the gates indicate the percentage of the
population. (B) Frequency of HIV-specific Tc17 and Tc1 cells in healthy individuals and PLWH. (C) Frequency of total Tc17 and Tc1 cells in healthy individuals and
PLWH. (D) Representative expression of CD161 in IL-17+ and IFN-γ+ CD8+ T-cells from a healthy individual, after PMA-ionomycin stimulation. The summary of the
median fluorescence intensity (MeFI) of the populations is shown below. (E) Gating strategy for the detection, after cell culture, of IL-17- and IFN-γ-producing
CD161-expressing CD8+ T-cells from a subject living with HIV. In the left zebra plots are shown non-stimulated cells. In the middle and right zebra plots are shown
PMA-ionomycin-stimulated cells where the anti-CD161 antibody was added before (middle panels) or after (right panels) cell permeabilization. The numbers indicate
the percentage of the populations. (F) Correlation between the frequency of total Tc17 (upper panel) and Tc1 (lower panel) cells and the frequency of circulating
CD161+ CD8+ T-cells in healthy individuals and PLWH. (G) Correlation between the frequency of HIV-specific Tc17 cells and the frequency of circulating CD161+
CD8+ T-cells in PLWH. In (G,H) the rho and P value of the Spearman test are shown. NS, Not statistically significant.
the subsets, without significant differences between them
(Figure 3K).
To further confirm the findings obtained with polyclonally-
stimulated cells, we performed an ACCENSE analysis to explore
the relationship between the activation markers with the
expression of IL-17 and IFN-γ in CD8+ T-cells. The t-SNE
analysis showed that, in healthy individuals, the expression of
IL-17 was particularly related with HLA-DR expression, and
in a lesser extent with CD38 expression, while this association
was not evidenced with IFN-γ-positive cells (Figure 3L, upper
panels). These associations were confirmed when the relative
expression of IL-17, HLA-DR and CD38 were correlated,
as a high positive correlation was found between these
parameters (Figure 3M). In contrast, a low correlation was
found between the relative expression of IFN-γ, HLA-DR,
and CD38 (Figure 3N). When these analyses were performed
in PLWH, similar associations between the expression of
IL-17, HLA-DR, and CD38 were found, but at a lower
degree than in healthy individuals (Figures 3L,M), as well
as for IFN-γ expression (Figures 3L,N). Interestingly, the
ACCENSE analysis also demonstrated the association between
the expression of IL-17 and IFN-γ, particularly in PLWH
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FIGURE 3 | Low frequency of activated Tc17 cells in PLWH. (A) Frequency of HLA-DR- and/or CD38-expressing non-stimulated and PMA-ionomycin-stimulated
CD8+ T-cells from PLWH. The 1 of the PMA-ionomycin/non-stimulated cells frequency is shown at the top. The P-value of the Wilcoxon test is shown. (B) Frequency
of HLA-DR- and/or CD38-expressing PMA-ionomycin-stimulated CD8+ T-cells from healthy individuals and PLWH. (C) Expression of HLA-DR and CD38 in IL-17+
and IFN-γ+ CD8+ T-cells after PMA-ionomycin stimulation in a representative healthy individual and patient living with HIV. (D) Representative pseudocolor plots of the
expression of IL-17 and IFN-γ in HLA-DR/CD38-expressing CD8+ T-cells after PMA-ionomycin stimulation in a representative healthy individual and patient living with
HIV. (E,F) Frequency of IL-17+ (E) and IFN-γ+ (F) cells among HLA-DR- and/or CD38-expressing PMA-ionomycin-stimulated CD8+ T-cells from healthy individuals
and PLWH. *Indicate which population, according to the expression of HLA-DR and CD38, had the highest frequency of IL-17+ or IFN-γ+ cells, respectively, when
healthy individuals or PLWH were analyzed independently (P ≤ 0.02, Dunn’s post-hoc test). (G) HLA-DR and/or CD38-expressing total Tc17/Tc1 cells ratio in healthy
individuals and PLWH. (H) Representative pseudocolor plots of the expression of IL-17 and IFN-γ in HLA-DR/CD38-expressing CD8+ T-cells after Gag peptides
stimulation in a representative patient living with HIV. (I,J) Frequency of IL-17+ (I) and IFN-γ+ (J) cells among HLA-DR- and/or CD38-expressing Gag-stimulated
CD8+ T-cells from PLWH. *P ≤ 0.04 vs. all the groups; Dunn’s post-hoc test. (K) HLA-DR and/or CD38-expressing HIV-specific Tc17/Tc1 cells ratio in PLWH. (L) Cell
ACCENSE t-SNE plots of CD8, HLA-DR, CD38, IL-17, and IFN-γ expression in polyclonally-stimulated cells from a representative healthy individual and a subject
living with HIV (M = 30,000). The black and red circles indicate, respectively, IL-17- and IFN-γ-positive CD8+ T-cells. (M,N) Correlation between the IL-17 (M) and
IFN-γ (N) relative expression units and that of CD38 and HLA-DR. A total of 30,000 cells were collected from all the healthy individuals and PLWH, and computed. The
r and P-value of the Pearson test are shown. In (B,E–G) the P-value of the Mann-Whitney test is shown. NS, Not statistically significant.
(Figure 3L). Nevertheless, by flow cytometry analysis we did
not detect total, CD161+ or activated CD8+ T-cells co-
expressing IL-17 and IFN-γ in any of the studied groups
(Figures 2E, 3D,H). Taken together, our results indicate that,
among total CD8+ T-cells, HLA-DR+ CD38+ cells are
the main source of IL-17 in healthy individuals, but not
in PLWH, despite their higher frequency after polyclonal
activation.
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The Low Response of HLA-DR+ CD38+
Tc17 Cells in PLWH Is Associated With the
Expression of CD38 and PD-1
Since the proportion of total HLA-DR+ CD38+ Tc17 cells
is decreased in PLWH despite the higher frequency of total
HLA-DR+ CD38+ CD8+ T-cells after polyclonal stimulation,
we asked which factors differentiate HLA-DR+ CD38+ Tc17
cells from healthy individuals and PLWH. Since the unique
expression of CD38, but not HLA-DR, has been associated to
CD8+ T-cells dysfunctionality (8), we hypothesized that the
density of expression of CD38 influenced the response of HLA-
DR+ CD38+ Tc17 cells in PLWH. Certainly, HLA-DR+ CD38+
Tc17 cells from PLWH had a higher MeFI of CD38, but not of
HLA-DR, than healthy individuals (Figure 4A). On the other
hand, HLA-DR− CD38+ Tc17 cells from healthy individuals
and PLWH did not show differences in the expression of both
activation markers (P ≥ 0.6, data not shown), suggesting that the
higher expression of CD38 in PLWH is restricted to HLA-DR+
CD38+ Tc17 cells.
In addition, we analyzed the HLA-DR+ CD38−/HLA-DR+
CD38+ CD8+ T-cells ratio, as a measure of the predominant
cell subset in PLWH. Of note, this ratio was lower in PLWH
in comparison with healthy individuals [median [range] of 1.3
[0.2–5.6] and 3.7 [1.3–10.2] in PLWH and healthy individuals,
respectively; P = 0.003]. Interestingly, a positive correlation was
obtained between the frequency of total HLA-DR+ CD38+ Tc17
cells and the HLA-DR+ CD38−/HLA-DR+ CD38+ CD8+ T-
cells ratio in PLWH, but not in healthy individuals (Figure 4B).
In addition, when the PLWH were classified according to their
HLA-DR+ CD38−/HLA-DR+ CD38+ CD8+ T-cells ratio (<1.9
and ≥2) and compared with healthy individuals, those PLWH
FIGURE 4 | The frequency of HLA-DR+ CD38+ Tc17 cells is associated with the CD38 and PD-1 expression, treatment duration and the levels of plasma sCD14 in
PLWH. (A) Expression of HLA-DR and CD38 in HLA-DR+ CD38+ Tc17 cells from healthy individuals and PLWH. In the right panel is shown the summary of the
individuals evaluated. (B) Correlation between the frequency of total HLA-DR+ CD38+ Tc17 cells and the HLA-DR+ CD38+/HLA-DR+ CD38− CD8+ T-cells ratio.
(C) Frequency of HLA-DR+ CD38+ Tc17 cells in PLWH with HLA-DR+ CD38+/HLA-DR+ CD38− CD8+ T-cells ratio <1.9 or ≥2, as well as healthy individuals. The
P-value of the Kruskal-Wallis and Dunn’s post-hoc test are shown. (D) Expression of PD-1 in HLA-DR and/or CD38-expressing CD8+ T-cells from healthy individuals
and PLWH. In the right panel is shown the frequency of PD-1+ HLA-DR and/or CD38-expressing CD8+ T-cells in healthy individuals and PLWH. (E) Correlation
between the frequency of total HLA-DR+ CD38+ Tc17 cells and the frequency of PD-1+ HLA-DR+ CD38+ CD8+ T-cells in healthy individuals and PLWH. (F)
Frequency of HLA-DR+ CD38+ Tc17 cells in PLWH who received HAART for <24 or ≥25 months. (G) Correlation between the frequency of total HLA-DR+ CD38+
Tc17 cells (red circles), the total HLA-DR+ CD38+ Tc17/Tc1 cells ratio (black squares) and the levels of plasma sCD14. In (A,D,F) the P-value of the Mann-Whitney
test is shown. In (B,E,G) the rho and P-value of the Spearman test are shown. NS, Not statistically significant.
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with a ratio<1.9, but not those with a ratio ≥2, had significantly
lower frequencies of HLA-DR+ CD38+ Tc17 cells (Figure 4C).
Of note, these findings were not observed for total HLA-DR−
CD38+, HLA-DR+ CD38− or HLA-DR− CD38− Tc17 cells
(P≥0.1, data not shown). Thus, the magnitude of total HLA-
DR+ CD38+ Tc17 cells is influenced by the expression of CD38,
and patients with predominant HLA-DR+ CD38− CD8+ T-cells
response conserve their frequencies of functional Tc17 cells.
Activated CD8+ T-cells usually also exhibit an exhaustion
state, which is widely evaluated by the expression of the
inhibitory receptor PD-1; this activation/exhaustion state of
CD8+ T-cells has been associated with disease progression
in HIV infection (4). Thus, we explored if the expression
of PD-1 is associated with the dysfunction of Tc17 cells.
Certainly, HLA-DR+ CD38+ and HLA-DR− CD38+ CD8+
T-cells in peripheral blood from PLWH had higher MeFI of
PD-1 than those from healthy individuals, as well as higher
percentages of PD-1+ cells (Figure 4D). Strikingly, the frequency
of PD1+ HLA-DR+ CD38+ CD8+ T-cells negatively correlated
with the frequency of total HLA-DR+ CD38+ Tc17 cells in
PLWH but not in healthy individuals (Figure 4E). Together,
these results indicate that the activation/exhaustion state of
CD8+ T-cells and the inhibitory effect of PD-1, persistently
increased during HIV infection despite HAART-induced viral
suppression, is associated with a low Tc17 cells response in
PLWH.
The Low Response of HLA-DR+ CD38+
Tc17 Cells Is Associated With the
Treatment Duration and Systemic Immune
Activation
We analyzed the association between the frequency of activated
Tc17 cells and several parameters, such as CD4+ and CD8+ T-
cells count, CD4:CD8 ratio, HAART scheme received, treatment
duration, and plasma sCD14, as a systemic activation marker
(29). Interestingly, a higher frequency of total HLA-DR+ CD38+
Tc17 cells, but not HLA-DR− CD38+, HLA-DR+ CD38− and
HLA-DR− CD38− cells, was found in patients receiving HAART
for more than 25 months in comparison with those with <24
months of therapy (Figure 4F and data not shown), suggesting
that the increase of this subset is associated to treatment duration.
On the contrary, we did not observe significant differences
when the frequency of Tc17 cells was analyzed according
to CD4+ and CD8+ T-cells count, CD4:CD8 ratio and the
HAART scheme received (P > 0.4, data not shown). Moreover,
PLWH had higher levels of sCD14 than healthy controls
[median [range] of 21.5 ng/mL [14.8–26.1] and 0.55 ng/mL
[0.18–2.4] in PLWH and healthy individuals, respectively; P <
0.0001, data not shown]. Interestingly, a significant negative
correlation was found between the frequency of total HLA-
DR+ CD38+ Tc17 cells, the total HLA-DR+ CD38+ Tc17/Tc1
cells ratio and plasma sCD14 levels (Figure 4G). Thus, the
low response of activated Tc17 cells, and a shift from Tc17 to
Tc1 profile is associated with an increased immune activation
state in PLWH, despite the suppression of HIV replication by
HAART.
SSZ Increases the Frequency of HLA-DR+
CD38+ Tc17 Cells From PLWH on HAART
To explore a potential immunomodulatory strategy for the
improvement of Tc17 cells response in PLWH under HAART-
induced viral suppression, we evaluated the anti-inflammatory
agent SSZ. Based on a previous report (24), we analyzed the effect
of SSZ on the decrease of the inflammatory environment and
the induction of death of activated T-cells, as well as its effect on
the production of IL-17 by CD8+ T-cells. To reproduce in vitro
the microbial translocation and the inflammatory environment,
PBMCwere treated for 24 hwith LPS to induce IL-1β secretion by
innate cells, in the presence or absence of SSZ, and subsequently
stimulated for 12 h with PMA and ionomycin to induce the
production of IL-17 and IFN-γ by CD8+ T-cells.
The anti-inflammatory effect of SSZ was confirmed by the
decrease of IL-1β levels in cell culture supernatant in comparison
with the untreated condition (Figure 5A), as this agent blocks
the activation of the nuclear factor (NF)-κB triggered by LPS-
TLR4 interaction (30), on which IL-1β transcription is dependent
(31). Next, we evaluated if SSZ induces the death of activated
CD8+ T-cells. Although the mortality of total PBMC from
PLWH after the SSZ treatment was <1%, when CD8+ T-cells
were analyzed separately, they had a median (range) of mortality
of 10.7% (9.5–12.3), which was significantly higher than in
cells without SSZ treatment (Figure 5B). Indeed, among total
non-viable PBMC after SSZ treatment, CD3+ CD8+ cells had
the highest proportion [median [range] of 49.9% [36.8-61.8]],
followed by CD3+ CD8− [median [range] of 22.2% [18.5–
28.3]] and CD3− CD8− cells [median [range] of 12.9% [6.2–
27.2]]. Similar results were obtained in PBMC from healthy
individuals (data not shown). Interestingly, among total non-
viable CD8+ T-cells after SSZ treatment, HLA-DR+ CD38+ cells
had the highest proportion, followed by HLA-DR− CD38+ and
HLA-DR+ CD38− cells (Figure 5B). To explore the type of cell
death induced by SSZ, PBMC from PLWH were cultured with
LPS plus SSZ in the presence or absence of the pan-caspase
inhibitor Z-VAD or the caspase-1 inhibitor Y-VAD, and the
frequency of death CD8+ T-cells was evaluated by the binding
of Annexin V and internalization of propidium iodide (PI),
respectively. As shown in Figure 5C, SSZ particularly induced
death of CD8+ T-cells, which was higher compared with cells
without SSZ treatment. Interestingly, the CD8+ T-cells death
was not prevented by Z-VAD or Y-VAD treatment (Figure 5C
and data not shown). Again, HLA-DR+ CD38+ and HLA-DR−
CD38+ cells had the highest proportion among total Annexin
V+ CD8+ T-cells, which have preserved membrane integrity and
low non-specific binding of stain antibodies (P = 0.02, data not
shown), confirming our results using the viability dye. Thus,
SSZ particularly induced caspase-independent death of activated
CD8+ T-cells.
Finally, we analyzed the effect of SSZ in the frequency of Tc17
cells. Interestingly, a significantly higher frequency of total Tc17
cells was found after SSZ treatment in comparison with untreated
cells, both in PLWH and healthy individuals (Figure 5D, upper
panels and data not shown). In addition, although SSZ also
increased the frequency of total Tc1 cells, it was not statistically
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FIGURE 5 | Sulfasalazine increases the frequency of total HLA-DR+ CD38+ Tc17 cells from PLWH. (A) Levels of IL-1β in culture supernatant from PBMC from
healthy or PLWH treated with LPS in the presence of medium or sulfasalazine (SSZ). The P-value of the Wilcoxon test is shown. (B) Gating strategy for the detection
of non-viable CD8+ T-cells in untreated and LPS-treated cells, the latter in the presence of medium or SSZ. The proportion of HLA-DR- and CD38-expressing
non-viable CD8+ T-cells after SSZ treatment is shown in the right. Zebra plots from a representative subject living with HIV are shown. The summary of the frequency
of total and HLA-DR- and CD38-expressing non-viable CD8+ T-cells in the respective conditions are shown. n = 3 healthy individuals and 6 PLWH. *P < 0.03 vs. all
the other groups. (C) Gating strategy for the detection of Annexin V and/or Propidium Iodide (PI)-positive CD8+ T-cells in untreated and LPS-treated cells, the latter in
the presence of medium, SSZ and SSZ plus Z-VAD. Zebra plots from a representative subject living with HIV are shown. The summary of the frequency of Annexin V+
CD8+ T-cells in the respective conditions is shown on the right. n = 4 PLWH. In (B,C) the P-value of the Kruskal-Wallis and Dunn’s post-hoc test are shown. (D)
Frequency of total Tc17 and Tc1 cells from a subject living with HIV after LPS treatment in the presence of medium or SSZ. The numbers in the zebra plots indicate the
(Continued)
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FIGURE 5 | percentage of the populations. The summary of the results is shown at the right. The 1 of the SSZ/medium-treated cells frequency is shown at the top.
(E) Frequency of IL-17+ (upper panel) and IFN-γ+ (lower panel) cells among HLA-DR- and/or CD38-expressing PMA-ionomycin-stimulated CD8+ T-cells from PLWH,
after LPS treatment in the presence of medium or SSZ. In (D,E) the P-value of the Wilcoxon test is shown. (F) Frequency of IL-17+ cells among HLA-DR- and/or
CD38-expressing PMA-ionomycin-stimulated CD8+ T-cells from healthy individuals and PLWH, after LPS treatment without (left panel) or with (right panel) SSZ. The
P-value of the Mann-Whitney test is shown. (G) Correlation between the frequency of non-viable (red circles) and total (black squares) HLA-DR+ CD38+ CD8+ T-cells
and that of IL-17-producing HLA-DR+ CD38+ CD8+ T-cells, all of them after LPS treatment in the presence of SSZ. The rho and P-value of the Spearman test are
shown. NS, Not statistically significant.
significant (Figure 5D, lower panels). Similarly, the frequency
of total HLA-DR− CD38+, HLA-DR+ CD38+, and HLA-DR+
CD38− Tc17, but not Tc1 cells, increased after SSZ treatment,
both in PLWH and healthy individuals (Figure 5E and data not
shown). Remarkably, similar to our previous results (Figure 3E),
the frequency of total HLA-DR+ CD38+ Tc17 cells from PLWH
was lower than those from healthy individuals in the presence
of LPS plus medium (Figure 5F, left panel), but it reached levels
similar to those from healthy individuals in the presence of SSZ
(Figure 5F, right panel). Of note, this effect was not evidenced in
HLA-DR− CD38+ Tc17 cells from PLWH, which despite their
higher response after SSZ treatment (Figure 5E, upper panel),
maintained lower frequencies in comparison with cells from
healthy individuals (Figure 5F), confirming the negative effect of
CD38 in the Tc17 cells response.
Ultimately, we hypothesized that the SSZ-induced increase
of total HLA-DR+ CD38+ Tc17 cells in PLWH was associated
with the preferential death of HLA-DR+ CD38+ CD8+ T-
cells. Certainly, after SSZ treatment, the frequency of total
HLA-DR+ CD38+ Tc17 cells was positively correlated with the
percentage of non-viable HLA-DR+ CD38+ CD8+ T-cells, but
negatively correlated with the frequency of HLA-DR+ CD38+
CD8+ T-cells (Figure 5G), consistent with an increase of Tc17
cells concomitant with the death and the decrease of activated
CD8+ T-cells. Of note, the MeFI of HLA-DR or CD38 in HLA-
DR+ CD38+ Tc17 cells were similar between SSZ-treated and
untreated cells (P≥0.3, data not shown), indicating that the death
of activated cells, but not the modulation of the expression of
these activation markers is the mechanism responsible for the
increase of the Tc17 cells frequency. In summary, through the
decrease of the inflammatory environment and induction of
death of activated –and possibly dysfunctional- CD8+ T-cells,
SSZ increased the frequency of HLA-DR+ CD38+ Tc17 cells from
PLWH.
DISCUSSION
Although their main localization is the gut and liver, circulating
CD161-expressing and IL-17-producing T-cells have also been
described (32, 33). Similar to a previous report (10), we found a
decreased frequency of circulating CD161-expressing CD4+ and
CD8+ T-cells, as well as a lower expression of CD161, in PLWH
despite HAART-induced viral suppression. Although we did not
evaluate, for instance, the Vα7.2-Jα33 T-cell receptor (TCR),
which characterizes mucosal associated invariant T (MAIT) cells,
the CD161-expressing CD8+ T-cells (and particularly CD161hi
cells) most likely constitute this population (34, 35), since
MAIT cells are characterized by high CD161 expression (36),
production of IL-17 (37) and are depleted in PLWH (38).
In addition, this population is also susceptible to activation-
induced cell death (38) and to CD161 downregulation (39),
particularly induced by microbial products, which are often
in circulation during HIV infection; this is consistent with
the lower MeFI and frequency of CD161-expressing T-cells
observed in our study. In addition, the increased microbial
translocation could induce the traffic of CD161-expressing
CD8+ T-cells from blood to gut mucosa (40). Certainly, the
loss of CD161-expressing CD8+ T-cells is associated to HIV
progression, evidenced by the preservation of their frequency
in HIV elite controllers (41). Additionally, similar to total
CD8+ T-cells, the expression of HLA-DR and CD38 is increased
in CD161+/MAIT-cells from untreated PLWH (42). However,
CD161-expresing CD8+ T-cells from our cohort of treated
PLWH exhibited similar activation levels to those from healthy
controls, indicating a HAART-induced normalization of these
parameters.
Since CD161 has been used as a marker of IL-17-producing
T-cells, we hypothesized that the frequency of total Tc17 cells
was also decreased in PLWH. Nonetheless, the frequency of
total Tc17 cells was comparable between PLWH and healthy
controls, similar to that of Tc1 cells. This finding was associated
to the downregulation of surface CD161 in CD8+ T-cells
after polyclonal stimulation, as previously reported (39, 42),
which hindered the previously established association between
CD161 expression and IL-17 production in healthy donors
(32). Of note, although in our experimental design, CD161
was dramatically down-regulated after polyclonal stimulation,
CD161+ cells sorted from peripheral blood from healthy donors
exhibit a high expression and secretion of IL-17, compared
with CD161− cells (9, 32). Indeed, the production of IL-
17 is dominated by CD161hi but not CD161int CD8+ T-cells
(32, 33), indicating that this subset is the predominant Tc17
population.
Interestingly, the production of IL-17 by total CD8+ T-
cells was associated with the expression of HLA-DR and
CD38, populations that had an increased frequency but lower
functionality in PLWH. This finding is similar to a previous
report, where dysfunctional CD8+ T-cells, particularly in their
degranulation ability, have been observed in patients on HAART
(43). Strikingly, HIV-specific Tc17 cells were preferentially
HLA-DR+ CD38+ cells, suggesting that these cells could be
also dysfunctional, as previously reported (3). In addition, a
preferential production of IFN-γ over IL-17 by total HLA-DR+
CD38+ CD8+ T-cells was found in PLWH, in agreement with
the depletion of circulating Tc17 but not Tc1 cells during chronic
lentiviral infections (44). Nonetheless, the HIV-specific Tc17/Tc1
cells ratio was close to one in HLA-DR and/or CD38-expressing
CD8+ T-cells, indicating that inHIV-specific cells is maintained a
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similar proportion between both profiles. It remains to be defined
if this is similar for other antigen specificities. Moreover, the
ACCENSE analysis showed a relationship between the expression
of IL-17 and IFN-γ in CD8+ T-cells, particularly in PLWH, that
was not evidenced by the detection of IL-17+ IFN-γ+ CD8+
T-cells by multiparametric flow cytometry. This is consistent
with the ability of t-SNE to identify small cellular subsets and
associations of markers at a single-cell resolution that might be
missed with conventional cytometry gating (45). These IL-17+
IFN-γ+ CD8+ T-cells could reflect the shift from the Tc17 to the
Tc1 profile in PLWH; in fact a similar shift has been previously
reported to be induced by IL-12 in mice (46). Overall, the
dysfunction of Tc17 cells could predispose PLWH to microbial
co-infections. In fact, low plasma IL-17 levels were associated
with mortality in PLWH (47).
Here we found that CD8+ T-cells from PLWH are prone
to activation after ex vivo polyclonal stimulation. Whereas
the co-expression of HLA-DR and CD38 has been associated
with high activation and dysfunction of CD8+ T-cells, the
single expression of each marker has a differential significance.
Thus, HLA-DR+ CD38− CD8+ T-cells have a better survival,
higher polyfunctionality, cytotoxicity and proliferative ability
than HLA-DR+ CD38+ CD8+ T-cells, and are preferentially
seen in HIV controllers (8, 48, 49). On the other hand, CD38+
CD8+ T-cells are prone to apoptosis (3) and are associated
with residual viral replication in patients receiving anti-retroviral
therapy (50). In agreement with the dysfunction of CD38-
expressing CD8+ T-cells, dysfunctional HLA-DR+ CD38+ Tc17
cells from PLWH had a higher expression of CD38, and the
predominance of more functional HLA-DR+ CD38− CD8+
T-cells was associated with a preserved IL-17 response. A
major concern is that most of the HIV-specific CD8+ T-cells
express CD38 (3, 51). Strikingly, the mechanism associated to
CD38-induced dysfunction in CD8+ T-cells is still undefined.
CD38 is an extracellular ADP-ribosyl cyclase which induces the
conversion of nicotinamide adenine dinucleotide to cyclic ADP-
ribose (cADPR), a molecule involved in the mobilization of
calcium stores, critical for cell activation. However, CD38 is also
a cADPR hydrolase, regulating its levels (52). Thus, it is possible
that in the context of persistent immune activation, CD38 has a
preferential cADPR hydrolase activity, impairing the functional
ability of CD8+ T-cells. In addition to chronic activation, CD8+
T-cells from PLWH are also characterized by an exhaustion state,
particularly evidenced by the expression of PD-1 (4), a receptor
that blocks the TCR signaling (53). Interestingly, the CD38/PD-1
co-expression is observed in most of HIV-specific CD8+ T-cells,
and has been positively correlated with viral load in untreated
PLWH (54). Thus, the negative effect of CD38 and PD-1 could
induce a greater dysfunction of CD8+ T-cells in PLWH, as we
observed for total HLA-DR+ CD38+ Tc17 cells. Together, ours
and previous reports indicate that CD38 and the concomitant
expression of PD-1 are major contributors to the dysfunctionality
observed in total and antigen-specific CD8+ T-cells in PLWH,
underscoring the need for therapeutic strategies that target these
molecules.
Despite the suppression of viral replication, HAART did
not restore the frequencies of circulating CD161-expressing
and HLA-DR+ CD38+ Tc17 cells, so that, in addition to viral
replication, the persistent inflammatory environment driven by
microbial translocation could be responsible for the alterations
in these CD8+ T-cell subsets (55). A longer treatment could
also be required for their normalization, as found for other
immunological markers (56) and in our case for HLA-DR+
CD38+ Tc17 cells. In addition, the negative correlation between
the percentage of HLA-DR+ CD38+ Tc17 cells, the HLA-DR+
CD38+ Tc17/ Tc1 cells ratio and plasma sCD14 levels in our
cohort of PLWH suggest that this subset is affected by the
persistent systemic activation; in addition, it might indicate that
these alterations associated to low levels of Il-17 contribute
to the systemic inflammation. Similar findings were obtained
for Th17 cells in simian immunodeficiency virus (SIV)-infected
macaques (57) and PLWH (58). Importantly, the frequency of
HLA-DR+ CD38+ Tc17 cells could constitute a novel cellular
marker of immune activation and/or reconstitution in patients
receiving HAART. Of note, we did not evaluate other functional
parameters in Tc17 cells, such as proliferation or secretion of
other cytokines. In this regard, a previous study demonstrated
a depletion of IL-17+ IFN-γ+ CD8+ T-cells in chronic SIV-
infected macaques, suggesting a defect in this population during
this lentiviral infection (44). However, to our knowledge, there
are no reports that have evaluated the proliferative capacity
of Tc17 cells in PLWH. Thus, it remains to be determined
if other functional capacities are altered in Tc17 cells from
PLWH.
Together, our results agree with an immune unbalance
and CD8+ T cells dysfunction in PLWH despite suppressive
HAART, which could contribute to morbidity or therapy
failure in scenarios of T cell activation, such as co-infections
and cardiovascular disease. Since systemic inflammation is
an important cause of morbidity in these individuals (59), a
major focus of research is the adjuvant administration of anti-
inflammatory agents that reduce, among other parameters, the
expression of HLA-DR and CD38 in CD8+ T-cells (17). In
this sense, SSZ could be a useful immunomodulatory strategy,
particularly in patients with inflammatory comorbidities. In
addition to the decrease of inflammatory cytokines via inhibition
of the NF-κB pathway, SSZ induces caspase-independent
death of activated -and possibly dysfunctional- CD8+ T-cells,
via the mitochondrio-nuclear translocation of the apoptosis-
inducing factor (AIF), that induces DNA fragmentation (24,
60). These effects led to an increase of the frequency of
total HLA-DR+ CD38+ Tc17 cells in PLWH to similar
levels found in healthy controls. Interestingly, SSZ-induced
cell death was preferentially observed in HLA-DR+ CD38+
and HLA-DR− CD38+ CD8+ T-cells, in agreement with the
lower expression of the anti-apoptotic protein Bcl-2 in CD38-
expressing CD8+ T-cells (8, 61). Indeed, Bcl-2 prevents the
SSZ-induced, AIF-mediated cell death (60). These mechanisms
also explain the beneficial effects of SSZ in the treatment of
chronic inflammatory disorders (21). Of note, it remains to
be determined the if SSZ treatment, through the decrease of
NF-κB-dependent cytokines such as IL-1β, IL-6, and IL-23,
affects Th17 or Tc17 cells polarization, as these cytokines are
important for their differentiation. Future studies that explore the
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mechanisms of SSZ in the restoration of particular CD8+ T-cell
populations are needed. Moreover, clinical trials that evaluate
HAART and SSZ co-treatment are required to establish the
usefulness of this approach for decreasing the systemic immune
activation state and the function of Tc17 cells in non-viremic
PLWH.
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